Transcranial magnetic stimulation, a non-invasive neuromodulation technique, uses magnetic pulses to influence neural activity in specific brain regions. Since receiving FDA approval in 2008 for major depressive disorder, TMS has grown in clinical utility, particularly for patients unresponsive to traditional pharmacological and psychotherapeutic interventions. Historically, determining the target site for TMS has relied on surface anatomical landmarks on the scalp, which serve as proxies for underlying brain structures. While pragmatically sound and easily accessible for widespread clinical use, this traditional approach lacks customization to the patient’s unique brain circuitry, potentially limiting therapeutic gains.

The innovation introduced by this study lies in leveraging functional magnetic resonance imaging (fMRI) to identify individualized treatment targets based on resting-state functional connectivity. This imaging modality measures synchronized activity patterns amongst disparate brain regions while subjects are at rest. By parsing these connectivity networks, the research team pinpointed precise loci within the brain circuits implicated in depression, thereby refining the spatial accuracy of stimulation. This neuroimaging foundation enables a more tailored intervention that accounts for the heterogeneity of depression at the circuit level.

Of particular note is the application of accelerated TMS (aTMS), which compresses multiple treatment sessions into a single day, thereby shortening the overall treatment course from several weeks to a mere week. This intensification not only improves patient convenience but may enhance neurobiological receptivity to stimulation by delivering more frequent pulses within a condensed timetable. The study set out to compare the clinical outcomes of aTMS when targets were defined by fMRI connectivity versus the established scalp-based targeting.

The trial enrolled 40 adult participants with moderate to severe treatment-resistant major depression, spanning a broad age range of 22 to 80 years. Each individual underwent pre-treatment fMRI scanning to delineate functional connectivity profiles. Subsequently, subjects were randomized to receive aTMS directed either at their individualized connectivity-based target or the conventional scalp-based target. Crucially, both patients and clinical raters were blinded to group assignments to mitigate bias.

One month post-treatment assessments revealed that the group receiving connectivity-guided aTMS demonstrated significantly greater alleviation of depressive symptoms compared to their scalp-based counterparts. These improvements were quantified using the Montgomery-Åsberg Depression Rating Scale (MADRS), a gold-standard clinician-administered instrument that sensitively captures changes in depression severity. Furthermore, the response rate — defined by clinically meaningful symptom reduction — was markedly higher in the connectivity group, with 80% responding versus 60% in the traditional targeting group, underscoring the potential clinical advantage of imaging-informed intervention.

This research builds upon prior explorations led by Joseph Taylor and colleagues, including investigations into imaging-based modulation of anxiety circuits within depressive populations, as recently reported in Molecular Psychiatry. These cumulative findings lend prospective support to the concept that precision neuroimaging can transcend theoretical neuroscience and play a direct role in augmenting therapeutic outcomes.

Taylor emphasizes the significance of closing the gap between neuroimaging research and tangible clinical benefit. Historically, the complexity and additional cost associated with imaging have created barriers to its routine clinical adoption for TMS guidance. This study represents a crucial step toward justifying such investment by empirically demonstrating a quantifiable benefit above conventional practice, a vital incentive for healthcare providers and payers considering integration of this technology.

Despite the promising results, the authors acknowledge particular study limitations, including the modest sample size and single-center study design, which may affect generalizability. They advocate for larger, multi-site trials to validate these early findings and explore durability of treatment effects over extended follow-up periods. Broadening the participant demographics will also be essential to ascertain the utility of connectivity-based targeting across diverse patient populations and varying clinical subtypes of depression.

This trial’s implications extend beyond depression, suggesting that functional brain imaging could inform individualized treatment strategies for a range of psychiatric disorders treatable by neuromodulation, including anxiety, obsessive-compulsive disorder, and post-traumatic stress disorder. As aTMS and neuroimaging technologies continue to evolve and become more accessible, the integration of connectivity-guided targeting holds promise for ushering in a new era of personalized psychiatry grounded in neurobiological precision.

In conclusion, the Mass General Brigham team’s randomized controlled trial provides compelling evidence that connectivity-based targeting via functional MRI can substantially enhance the antidepressant impact of accelerated TMS treatment in individuals with refractory depression. This approach offers a paradigm shift toward precision-guided neuromodulation, with the potential to improve patient outcomes and redefine clinical standards for brain stimulation therapies in psychiatric care.

Subject of Research: People

Article Title: Connectivity- versus scalp-based targeting of accelerated TMS for depression: A randomized trial

Web References:

• https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1100
• https://www.massgeneralbrigham.org/en/about/neuroscience-institute
• https://www.massgeneralbrigham.org/en/about/complex-psychiatric-care

References:
Taylor, J. et al. “Connectivity- versus scalp-based targeting of accelerated TMS for depression: A randomized trial,” JAMA Psychiatry, DOI: 10.1001/jamapsychiatry.2026.1100

Keywords:
Depression, Transcranial magnetic stimulation, Accelerated TMS, Functional magnetic resonance imaging, Functional connectivity, Neuroimaging-guided neuromodulation, Treatment-resistant depression, Personalized psychiatry, Montgomery-Åsberg Depression Rating Scale

Major depressive disorder remains one of the most pervasive and debilitating mental health conditions globally, affecting millions of individuals and posing substantial clinical challenges due to variable treatment responses. Conventional pharmacotherapy and psychotherapy, while beneficial for many, fail to yield consistent results across the board, prompting the exploration of neuromodulation techniques, such as transcranial magnetic stimulation (TMS). Among these, intermittent theta-burst stimulation stands out for its capacity to induce more robust and rapid neuromodulatory effects, though the mechanisms underlying its efficacy remain incompletely understood.

The focus of the recent investigation was to decode the role of white matter architecture in modulating physiological responses to iTBS, specifically heart rate deceleration, which serves as an index for autonomic nervous system regulation. Heart rate variability and deceleration are deeply entwined with emotional and cognitive processes, reflecting the communication between central autonomic networks and the peripheral cardiovascular system. Understanding these connections opens a promising window into not only how brain structure may influence treatment responsiveness but also how systemic physiological changes accompany psychiatric interventions.

This study employed a sophisticated neuroimaging approach, leveraging diffusion tensor imaging (DTI) to map the microstructural integrity of white matter tracts across the brain. By correlating these imaging metrics with heart rate changes induced by iTBS, the researchers identified specific tracts whose structural properties were strongly predictive of both acute physiological responses and longer-term clinical improvement. Such insights provide a nuanced understanding of the underpinnings of therapeutic efficacy in neuromodulation.

One remarkable finding from the investigation was the identification of key white matter pathways linking the prefrontal cortex to subcortical and autonomic centers as critical mediators. The prefrontal cortex, long implicated in executive function and mood regulation, appears to exert downstream influence on cardiac control through these neural highways. The integrity and connectivity of these tracts, therefore, may determine the magnitude of heart rate deceleration following iTBS, effectively serving as a neuroanatomical substrate for treatment response.

The implications are profound—this correlation signals that the structural brain blueprint inherent to each individual could potentially forecast their response to iTBS therapy. This knowledge empowers clinicians to tailor treatment plans, advancing towards the era of personalized psychiatry where interventions are optimized based on an individual’s neural circuitry to maximize efficacy and minimize adverse effects. It fundamentally shifts the paradigm from a one-size-fits-all approach to a more stratified, biomarker-guided methodology.

Delving deeper into the physiological dimension, heart rate deceleration captured during the study reflects parasympathetic activity, primarily mediated by the vagus nerve. The vagal tone is considered a hallmark of flexible emotional regulation and adaptive responses to stress. Enhancing vagal tone through iTBS might not only ameliorate mood symptoms but also fortify autonomic balance, reducing cardiovascular risks commonly associated with depression. This dual benefit underscores the holistic potential of neuromodulation therapies.

Moreover, the study’s methodology highlights how advanced imaging techniques can be seamlessly integrated with physiological monitoring to unravel complex brain-body interactions. The temporal precision of iTBS paired with continuous heart rate tracking enables researchers to capture dynamic neurocardiac synchrony, opening new vistas for exploring central-autonomic coupling in mental health and disease. These techniques herald a new frontier in psychoneurocardiology.

Crucially, the research addresses the heterogeneity of major depressive disorder by anchoring treatment response to neuroanatomical signatures rather than symptom clusters alone. The heterogeneity in white matter integrity among patients may partly explain why some individuals display pronounced heart rate deceleration – and better clinical outcomes – following iTBS, while others do not. This variability calls for more expansive studies but offers a hopeful pathway to deciphering MDD subtypes through neuroimaging biomarkers.

Another notable aspect of the study is its contribution to understanding the mechanistic pathways evoked by iTBS. Theta-burst stimulation is posited to engage synaptic plasticity mechanisms akin to long-term potentiation, promoting neural circuit remodeling. The present findings suggest that such plasticity may be constrained or facilitated by the structural scaffolding that white matter provides, emphasizing the interplay between brain architecture and the functional modulation of neural networks during treatment.

The convergence of neuroimaging, cardiophysiology, and clinical data presented in this research exemplifies the multidisciplinary collaboration needed to tackle the complexities of neuropsychiatric disorders. By integrating these domains, the study carves a pathway for future investigations to harness multimodal biomarkers for refined diagnostics and therapeutic monitoring in depression and other psychiatric illnesses.

Furthermore, this work paves the way for exploration into whether similar white matter correlates could predict responses to other neuromodulatory interventions, such as deep brain stimulation or electroconvulsive therapy, broadening the clinical utility of structural brain imaging. The connectivity patterns observed may represent general principles of brain-autonomic interactions relevant across various treatment modalities.

The potential for clinical translation of these findings is immense. Non-invasive imaging prior to iTBS treatment could become a routine screening step, enabling clinicians to stratify patients who are likely to benefit most, thereby optimizing resource allocation and improving overall treatment success rates. Additionally, heart rate monitoring during sessions could offer real-time feedback on treatment engagement and effectiveness, facilitating adaptive adjustment of stimulation parameters.

This study also raises pertinent questions about the plasticity of white matter tracts themselves. Does repeated iTBS induce measurable changes in white matter integrity over time? Could enhancing connectivity in specific pathways amplify treatment effects? These queries open an exciting vista for longitudinal research to track structural neuroplasticity concurrent with neuromodulation therapy.

In conclusion, the revelation that white matter tract integrity governs heart rate deceleration induced by iTBS and aligns with therapeutic outcome in major depressive disorder elevates our comprehension of brain-heart interactions in psychiatric treatment. It underscores the transformative potential of combining neuroimaging with physiological markers to forge personalized, mechanism-based interventions, propelling the field toward more precise and effective care for depression sufferers worldwide.

Subject of Research: White matter tracts related to iTBS-induced heart rate deceleration and treatment response in major depressive disorder.

Article Title: White matter tracts associated with iTBS-induced heart rate deceleration and treatment response in major depressive disorder.

Article References:
Wilkening, J., Goya-Maldonado, R. White matter tracts associated with iTBS-induced heart rate deceleration and treatment response in major depressive disorder. Transl Psychiatry 15, 424 (2025). https://doi.org/10.1038/s41398-025-03646-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03646-3